Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
← catalyst calendarSponsored by Hansa Biopharma AB (industry) · HNSA.ST — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
113actual
Sites
22
Countries
Austria, Belgium, Czechia +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-04-19 | actual | When the study began enrolling |
| Primary completion | 2026-04-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-21 | actual | The whole study's end, after follow-up |
| First posted | 2022-05-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Kidney Transplantation in Highly Sensitized Patients
Interventions
- Drug: Imlifidase — also filed as IdeS, HMED-IdeS
- Other: Normal Transplantation Routine
Primary outcome
what the primary-completion date above is the date OFGraft failure-free survival 1 year after transplantation following imlifidase treatment
measured 12 months after transplantation
Publications
- PMID 38995690 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · HNSA.ST's whole pipeline · Catalyst calendar · Every registered study · What changed